A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma

StatusTerminated
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial terminated Sponsor's reason: This was a strategic business decision. There were no safety concerns contributing to this decision.
    • Eligibility criteria expanded, about 24 words
    • Site details revised at 1 of 77 sites
  2. Re-verified, no change to tracked fieldsv43
  3. Primary completion date: Dec 31, 2025 to Sep 28, 2026
    • Study completion date: Dec 31, 2026 to Sep 28, 2026
    v42
  4. Study Status, Referencesv41
  5. 2 versions Re-verified since Jan 6, 2025, no change to tracked fieldsv39-v40
Show 37 earlier versionsHide 37 earlier versions
  1. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 240 to confirmed 63
    • Study sites: 79 to 77
    v38
  2. Study sites: 78 to 79v37
  3. Study sites: 79 to 78v36
  4. Study sites: 113 to 79v35
  5. Study sites: 112 to 113v34
  6. Site details revised at 2 of 112 sitesv33
  7. Study sites: 113 to 112v32
  8. Study sites: 112 to 113v31
  9. Study sites: 113 to 112v30
  10. Study sites: 111 to 113v29
  11. Site details revised at 1 of 111 sitesv28
  12. Study sites: 108 to 111v27
  13. Site details revised at 2 of 108 sitesv26
  14. Study sites revised (108)v25
  15. Study sites revised (108)v24
  16. Site details revised at 5 of 108 sitesv23
  17. Site details revised at 1 of 108 sitesv22
  18. Site details revised at 1 of 108 sitesv21
  19. Study sites: 107 to 108v20
  20. Study sites revised (107)v19
  21. Study sites: 106 to 107v18
  22. Site details revised at 4 of 106 sitesv17
  23. Site details revised at 1 of 106 sitesv16
  24. Site details revised at 2 of 106 sitesv15
  25. Site details revised at 3 of 106 sitesv14
  26. Site details revised at 3 of 106 sitesv13
  27. Site details revised at 1 of 106 sitesv12
  28. Site details revised at 7 of 106 sitesv11
  29. Site details revised at 4 of 106 sitesv10
  30. Study sites: 105 to 106v9
  31. Site details revised at 1 of 105 sitesv8
  32. Site details revised at 5 of 105 sitesv7
  33. Start date changed from estimate of Sep 28, 2023 to Oct 9, 2023
    • Study sites revised (105)
    v6
  34. Study sites: 106 to 105v5
  35. Start date: Aug 28, 2023 to Sep 28, 2023
    • Study sites: 105 to 106
    v4
  36. Study sites: 106 to 105v3
  37. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Jun 16, 2023 to Aug 28, 2023
    • Study sites: 0 to 106
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Incyte
94 trials monitored
See 7 trials at risk
This study is being conducted to determine the safety, tolerability, and preliminary efficacy of INCB099280 in participants with advanced Cutaneous Squamous Cell Carcinoma.
Trial Details
NCT Number NCT05888844
Lead Sponsor Incyte Corporation
Conditions
(from sponsor)		 Cutaneous Squamous Cell Carcinoma
Enrollment 63 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov